Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment

scientific article

Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1038208710
P356DOI10.1007/S10096-016-2809-3
P698PubMed publication ID27848039

P50authorTheodore LytrasQ58485725
Emmanouil AntalisQ88424871
Sotiris TsiodrasQ37830054
P2093author name stringA Meijer
P Karakitsos
A-F A Mentis
K Tryfinopoulou
A F Mentis
A Kossyvakis
A Kalliaropoulos
V Pogka
P2860cites workThe epidemiology and spread of drug resistant human influenza virusesQ38215346
NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.Q41030411
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.Q41344703
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in ratsQ43166298
Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patientQ43186856
Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012.Q44616840
Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.Q45369153
Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccineQ45382232
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.Q45947329
Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 InfluenzaQ57077387
Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012Q95438587
Neuraminidase inhibitors for preventing and treating influenza in adults and childrenQ24197463
MEGA6: Molecular Evolutionary Genetics Analysis version 6.0Q24498082
Acute emergence and reversion of influenza A virus quasispecies within CD8+ T cell antigenic peptidesQ27687391
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceQ28282405
Coordinated Evolution of Influenza A Surface ProteinsQ28547048
Rational design of potent sialidase-based inhibitors of influenza virus replicationQ29616647
Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.Q30372482
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.Q30390856
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenzaQ30396231
A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidaseQ30405350
Influenza surveillance during the post-pandemic influenza 2010/11 season in Greece, 04 October 2010 to 22 May 2011.Q30409510
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.Q30412554
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.Q30445738
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug designQ31440495
Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) virusesQ34102756
Permissive secondary mutations enable the evolution of influenza oseltamivir resistanceQ34118992
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trialsQ34460803
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activityQ34565520
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancerQ34759825
Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14.Q34843761
Challenges in antigenic characterization of circulating influenza A(H3N2) viruses during the 2011-2012 influenza season: an ongoing problem?Q35455493
Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.Q36048315
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 seasonQ37164761
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.Q37169942
Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sitesQ37215150
P433issue2
P304page(s)361-371
P577publication date2016-11-15
P1433published inEuropean Journal of Clinical Microbiology & Infectious DiseasesQ15754378
P1476titleAntiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment
P478volume36

Reverse relations

cites work (P2860)
Q58614971Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus
Q40094068Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection
Q91173936Rapid functionalisation and detection of viruses via a novel Ca2+-mediated virus-DNA interaction
Q93160589Severity and outcomes of influenza-related pneumonia in type A and B strains in China, 2013-2019

Search more.